Androgenetic Alopecia – Pipeline Review, 2025

The global Androgenetic Alopecia Pipeline is developing rapidly because the number of patients with the condition is increasing and people search for new treatments that are effective for a long period. Male- or female-pattern baldness, also called androgenetic alopecia, is a frequent hereditary condition found in up to 50% of both men and women. Most people experience its onset after puberty and it grows slowly over time. With men, baldness starts happening at their hairline and crown in an “M” pattern, whereas women develop diffuse thinning on their scalp and their front hairline is often spared. When a man has male pattern hair loss, his scalp experiences higher dihydrotestosterone, 5 alpha-reductase and androgen receptors. Usually, the diagnosis is made at the doctor’s office with a check of family history. Minoxidil and finasteride, approved by the FDA, need to be used regularly to see and maintain positive effects.

Androgenetic Alopecia Pipeline Insights 2025: Report Scope

Covering 2+ pipeline drugs from 2+ companies, Fortune Business Insights has released this report titled “Androgenetic Alopecia Pipeline Insight 2025”. The report includes a complete study of pipeline drug development for androgenetic alopecia, considering their development stage, form of administration, type of medicine, supporting organization, structure, target and disease being treated. Every drug candidate gets a presentation with summaries that include company background, product details, R&D news, its mechanism, clinical updates and funding information. Available data on withdrawn or inactive participants is provided in the report, together with an eye on current market trends and androgenetic alopecia occurrences. The key regions covered in the report include North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Reasons to Buy this Report

• Use the results of a thorough drug R&D analysis and study of pipeline candidates for androgenetic alopecia to develop powerful ways to boost the market.


• Find new companies working in androgenetic alopecia and create plans to stay ahead of the competition.


• Examine which areas and strategies top companies use to advance androgenetic alopecia treatments.


• Look for promising partnerships or potential acquisitions by examining actively pursued research collaborations and development work.


• Study why some pipeline candidates were stopped so as to improve product development and guide future research efforts.

Know Answers to Your Questions

• How many companies are currently involved in the development of drugs for androgenetic alopecia?


• What is the distribution of androgenetic alopecia drug candidates across the companies developing them?


• How many investigational drugs for androgenetic alopecia are in mid- and late-stage clinical development?


• What are the major collaborations—including industry–industry and industry–academia partnerships—as well as mergers, acquisitions, and licensing deals in the androgenetic alopecia therapeutic space?


• What are the latest trends, drug classes, and innovative technologies being explored to address the limitations of current treatments?


• What clinical trials are currently underway for androgenetic alopecia, and what is their current status?


• What regulatory designations have been granted to emerging drug candidates in this therapeutic area?

Report Methodology

• Mostly, the pipeline reports are created through desk research plus secondary research that includes interviews with senior experts and important figures.


• Some examples of desk research sources are global and regional websites for clinical trials, company annual reports, official websites, press releases, presentations for investors, white papers, publications by industry associations, news outlets and scientific journals on NCBI, ResearchGate or the databases used internally.

Clinical Trial Insights

More effective and accessible treatments are being sought by patients which drives the development of new treatments for androgenetic alopecia. Lots of healthcare establishments, drug research companies and research centers are busy conducting clinical trials to establish new therapies. Emphasizing better healthcare infrastructure now motivates more research into androgenetic alopecia worldwide. Current studies are working to create better treatments, especially to improve treatment for loss of contrast sensitivity and difficulties with colors. At the same time, research trials aim to address the drawbacks of current treatments and give new options for managing disease-related inflammation.

Androgenetic Alopecia Pipeline Overview

The report includes information on drug candidates in the Androgenetic Alopecia space, at every stage from research to clinical trials- phase 1 trials, phase 2 trials and phase 3 trials. Because of the support from the government and more informed public knowledge, lots of pharmaceutical companies and research centers are beginning strong projects to develop new medications. Strategic mergers, acquisitions and license agreements are helping a number of new therapies as they move through clinical trials data aimed at fast-tracking progress and gaining stability. Besides collaborating, industry players are working toward gaining approvals from regulators to enter the market fast. It further provides information on recent clinical studies, how different medications act and the current collaborations, promotional activities and science behind the treatments for androgenetic alopecia.

Here is a brief overview of some promising drugs currently in the pipeline:

KX-826 – Kintor Pharma

Developed by Kintor Pharma, KX-826 could be the first topical androgen receptor (AR) antagonist for treating androgenetic alopecia (AGA) and acne vulgaris. In September 2021, the business reported that the Phase II trial with adult male AGA cases delivered efficacious results and had a positive safety record. Initially, on July 11, 2021, the FDA approved starting Phase II clinical trials of KX-826 for AGA in the U.S.

Clascoterone – Cassiopea

Cassiopea developed clascoterone 7.5% solution as a new AR inhibitor to tackle androgenetic alopecia by stopping dihydrotestosterone (DHT) from bonding with androgen receptors in scalp hair follicles. It could fight hair loss caused by DHT. The data from a Phase II dose-ranging study in males were reviewed in early 2019 and with no serious safety issues, the company chose to move forward with the 7.5% formulation in Phase III adult male clinical trials. Clinical research testing its effectiveness in women with AGA is progressing and the main results are expected by the end of Q3 2021.